Skip to search formSkip to main contentSkip to account menu

PF-05212384

Known as: PF 05212384 
National Institutes of Health

Related topics

Related topics

1 relation
PKI 587

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.
2566Background: Inhibition of phosphatidylinositol-3-kinase (PI3K)-mediated signaling may overcome resistance to chemotherapy or… 
2015
2015
Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Purpose: Targeted treatment of solid or liquid tumors with antibody–drug conjugates (ADCs) can lead to promising clinical benefit… 
2015
2015
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
2590 Background: Inhibition of phosphatidylinositol-3-kinase (PI3K)-mediated signaling may overcome resistance to different… 
2015
2015
Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models
Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor of ALK, ROS1 and c-MET that is approved in over 70… 
2015
2015
First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer
Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity… 
2014
2014
Decatenation checkpoint‐defective melanomas are dependent on PI3K for survival
Melanoma cell lines are commonly defective for the G2‐phase cell cycle checkpoint that responds to incomplete catenation of the… 
2014
2014
Abstract 3121: Evaluation of novel combinations of PI3K-mTOR inhibitors with dacomitinib (dac) or chemotherapy in PTEN-deficient genomically characterized patient-derived tumor xenografts (gPTX)
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Activation of the PI3K pathway has been… 
2013
2013
Abstract 322: Dual targeting of the PI3K/mTOR pathways by PF-04691502 or PF-05212384 exhibits therapeutic effects against the metastatic disease progression in the Ovcar 3 disseminated model.
Ovarian cancer has the highest mortality rate of all gynecological cancers primarily due to the high incidence of metastatic… 
2012
2012
358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK…
2012
2012
Abstract 2817: Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The PI3K pathway plays a pivotal role in many… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)